This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Review -
Olympic sports and transsexuals
Louis J. Gooren
Departmen of Endocrinology, VU University Medical Center, Amsterdam 1007 MB, the Netherlands
Abstract
Sex segregation in competitive sports is regarded as fair. Before puberty boys and girls do not differ in height,
muscle and bone mass. Testosterone (T) exposure during puberty leads to an ultimate average greater height in men
of 12_15 cm, longer and larger bones and muscle mass and strength and higher hemoglobin levels. Postpubertal
androgen ablation reverses, at least in part, previous anabolic effects of T on muscle, bone mineral density and
hemoglobin but the long bones remain longer and wider. T administration dose dependently increases muscle mass
and maximal voluntary strength. Therefore, exogenous androgens, being performance enhancing drugs, are banned
for all athletes. An issue is the participation in competitive sports of people with errors of sexual differentiation and
particularly transsexuals who have been sex-reassigned. In view of the effects of T, a clear demarcation is whether
sex reassignment has taken place before or after hormonal puberty. Pubertal effects of T are in part reversible but
there is no reliable evidence as to its completeness. The International Olympic Committee (IOC) has taken an
inevitably arbitrary decision with regard to participation of sex-reassigned transsexuals in elite sports: sex
reassignment must have taken place at least two years earlier, hormone treatment must be appropriate for the reassigned sex
and the reassigned sex must be legally recognized. The IOC policy is not binding for other
organizations. (Asian J Androl 2008 May; 10: 427_432)
Keywords: sports; sex difference; gender; testosterone; muscle
Correspondence to: Prof. Louis J. Gooren, Department of Endocri-nology, VU University Medical Center, P.O.Box 7057, Amsterdam
1007 MB, the Netherlands.
Tel: +66-8961-27650 Fax +31-2044-40502
E-mail: ljgooren@truemail.co.th
Received 2007-11-14 Accepted 2007-11-20
DOI: 10.1111/j.1745-7262.2008.00378.x
1 Introduction
There is wide agreement that sex segregation in competitive sports is defensible and fair. As adult men have
inherent performance advantages over women due to their average greater height and muscle mass and
power, sex specific competitions provide women with a countervailing advantage.
This difference is largely based on correspondingly different exposures to androgens from the onset of puberty.
Before puberty boys and girls do not differ in height, muscle and bone mass [1] though girls have more truncal
fat. Testosterone (T) exposure during puberty leads to an ultimate average greater height in men of 12_15
cm, larger and longer bones and muscle mass and strength and higher hemoglobin levels. Clinical and experimental studies show
that androgen deprivation reverses, at least in part, previous anabolic effects of T on muscle, bone and hemoglobin
[2]. But the pubertal effects of T producing a greater length, diameter and thickness of bones in men, is not reversed
upon androgen ablation. T administration dose dependently increases muscle mass and maximal voluntary strength
but not fatigability or specific tension [3].
So, to overcome the physical disadvantages, sex specific competitions for women are allowed and there is
therefore a legitimate need to establish the sex of people who engage in competitive sports. The question is: can
this be done in a way that is scientifically well founded and is fair to those who wish to engage in competition.
In the vast majority of sports people's determination of sex is not an issue. They will have a history of having been
born and grown up unambiguously as male or
female. The problems arise in those for whom this has not been the case.
Genotyping (determination of Barr bodies in buccal smears) has been the established means of determining sex
for competition in sports. The results were unsatisfactory and as a result this criterion has been dropped since the
year 2000 [4]. Chromosomal sex, when taken as the sole criterion for the purpose of ensuring fair competition in
sports, is, indeed, not a particularly adequate indicator.
In humans, there is no solid evidence that the pattern of
sex chromosome has a direct effect on muscle mass and strength. Rather, the influence is indirect through
determination of the nature of the embryonic gonadal
anlagen (testis or ovary) and their hormonal products
(T and estradiol and their quantitative relationship). Also
other criteria (the nature of the gonad, sex hormones
and genitalia) do not provide workable criteria to
determine sex and gender of human beings. The implication
is that in humans, manhood and womanhood cannot be
assessed by laboratory techniques alone but require
additionally a self-description of one's gender identity/role.
In sports, previous and present exposure to androgens
is a reasonable criterion for reducing unfair competition.
In a series of studies Bhasin and coworkers [5] have
demonstrated that there is a positive correlation between
blood T concentrations and leg press strength, thigh
and quadriceps muscle volume, and levels of
hemoglobin and insulin-like growth factor-1 (IGF-1), and that
the anabolic response to T can largely be predicted by
the dose administered [6]. This dose-response curve
between T and muscle properties goes linearly beyond
the physiological range but does not seem to apply to
bones mass/strength.
2 People with disorders of sexual differentiation
and sports
Some children are born with ambiguous genitalia, a
perplexing discovery for parents. A child born with
ambiguous genitalia constitutes a psychosocial emergency
in which sex assignment must take place without much
delay, rather over days than over weeks. A
socio-cultural given of the human condition is an absolute
dichotomy between male and female with regard to sex.
In cases of genital ambiguity, modern techniques such
as karyotyping, molecular biology, and imaging
techniques allow a rather precise diagnosis of the condition,
but decisions regarding sex assignment are still based on
very limited empiric data [7].
The widely adopted policy nowadays is to arrive at
a prognosis on the "optimal sex" for the newborn, the
elements of which are an overall sex-appropriate
appearance with stable gender identity, good sexual function
(preferably combined with reproductive function if
attainable), minimal medical procedures, and a
reasonably happy life given the limitations [7]. To those
without experience in this area this policy might seem erratic,
but the outcome studies show that this is an acceptable
practice for patients, though there should be room for
later sex reassignment if the subject experiences the
assigned sex as incongruous [8, 9]. The implication of
contemporary medical practice is that, ultimately, there
is no single solid biological criterion for the
determination of sex for the purpose of sex assignment of children
with genital ambiguity. When a criterion is needed for
sex for a specific purpose, the optimal solution seems to
be to adopt a criterion that serves best the purpose for
which it is needed. In sports, previous and present
exposure to androgens is a reasonable criterion for
reducing unfair competition. Nowadays most intersexed
subjects are identified early in life, if not immediately
postnatally. Usually, before they engage in sports, they
have received long-term endocrine treatment, the nature
of which being determined by their sex of assignment.
This is consistent with the International Olympic
Committee's (IOC) policy on gender verification
requiring a two-year period of stable gender re-assigment.
3 Transsexualism
Transsexualism is the condition in which a person
with apparently normal somatic sexual differentiation has
the unshakeable conviction that he or she is actually a
member of the other sex. This conviction is
accompanied by the irresistible urge to live in the gender
experienced as self, which requires hormonal, anatomical, legal,
and psychosocial adaptations. Psychological assessment
may conclude that sex reassignment will bring relief to
an individual suffering from gender dysphoria_the
extreme feeling often described as being "trapped in the
wrong body"_and may result in an indication for
hormone and surgical treatment of transsexuals.
Increasingly, countries are offering transsexuals who
have undergone sex reassignment procedures, the
possibility to change their legal sex to allow them to take
part in public life, with the same rights as anyone born
into that sex. The practical implementation of this policy
may involve complex and difficult decisions. As with
other intersexed individuals, the medical and legal
system is being called upon to humanely provide a safe space
for these people to function as men or women with as
little needless hindrance as possible, yet consistent with
the gender bipolarity of modern human society.
The acquisition of the secondary sex
characteristics of the other gender, to the fullest extent possible, is
fundamental to sex reassignment for the transsexual
patient. Obviously, acquisition of these secondary sex
characteristics is contingent on sex steroids. At least in
the rat, no essential difference in sensitivity to the
biological action of sex steroids on the basis of genetic
configurations or gonadal status has been demonstrated [10].
The typical transsexual requesting treatment is a young
to middle-aged and usually healthy person.
4 Physical changes following administration of
cross-sex hormones postpubertally
Since 1975, the gender clinic of the Vrije Universiteit
in Amsterdam, the Netherlands, has provided sex
reassignment treatment to more than 3 000 transgendered
people.
The physical changes resulting from cross-sex
hormone administration have been reported [11_13]. The
standard hormone treatment before sex reassignment
surgery in male-to-female transsexuals (M2F) is
combination of anti-androgen with estrogens. In Europe, the
most widely-used drug is cyproterone acetate (usually
50 mg twice daily), a progestational compound with
anti-androgenic properties. If not available,
medroxyprogesterone acetate, 5 to 10 mg/day, is a less effective
alternative. Long-acting gonadotrophin-releasing
hormone agonists (GnRH), injected monthly, also inhibit
gonadotropin secretion [14]. Finasteride (5 mg/day), a
5α-reductase inhibitor, might also be considered. The latter
drug but none of those mentioned previously are banned
by the IOC. Sex reassignment surgery including gonadectomy, usually takes place following two years
of cross-sex hormones. Then anti-androgen treatment
in M2F transsexuals is usually stopped, while estrogen
treatment continues.
Female-to-male transsexuals (F2M) receive treatment
with T. The most commonly used preparations are T
esters, an injectable administered intramuscularly in doses
of 200 to 250 mg every two weeks. In some countries,
parenteral T undecanoate (1 000 mg) is available, and
injections may be spaced at 10_12 weeks [15, 16].
After ovariectomy, androgen treatment in F2M subjects is
continued at a dosage level as administered to hypogonadal
men. In this regard the situation of F2M (and intersexed
individuals assigned to the male sex) is comparable to
the situation of agonadal/hypogonadal men receiving T
replacement and would require approval for all elite
competitive athletes.
While principally administration of exogenous T is
prohibited for participants in competitive sports, it is the
policy now to allow medically indicated T replacement
in men provided T blood levels have not exceeded and
do not exceed those that naturally occur in men with
normal testicular hormone production. This goal is
difficult to attain with the traditional T esters whose
pharmacokinetic profile is characterized by peaks and troughs
of circulating levels of T [17]. Use of implantable or
transdermal depot preparations may be more compliant
with this idealized requirement.
5 Physical changes in transsexuals following
cross-sex hormone treatment postpubertally
Androgen deprivation in M2F and androgen admi-nistration to F2M have consistent effects on the following
variables: plasma T levels, muscle mass measured with
MRI at the level of the thigh, levels of haemoglobin and
IGF-1 [18_20] (Table 1). The results of androgen
deprivation plus estrogen treatment in M2F are compared to
the findings in F2M before T administration, and vice versa
the results of T administration in F2M are compared to
the findings in M2F before androgen deprivation plus
estrogen administration (Table 2).
Androgen deprivation plus estrogen administration of
M2F decreased plasma T to castrate levels and reduced
muscle area significantly after one year of treatment,
with no further reduction after three years of hormones.
Hemoglobin levels decreased significantly and values
after one and three years hormone administration were
not different, and the latter were not different from values
in F2M before T administration. After one year of
cross-sex hormones values of plasma IGF-1 fell significantly
to levels lower than in F2M before T
administration.
In F2M T administration increased plasma T levels
to values above the reference range for eugonadal men
(12_28 nmol/L). After 1-year muscle area, levels of
hemoglobin and IGF-1 were in the same range as in M2F
before cross-sex hormones, with no further increases in
muscle area and hemoglobin levels after 3 years of T
administration.
In spite of the of the cross-sex hormone induced
reduction, mean muscle area in M2F after 1 year of
hormones remained significantly greater than in F2M before
T treatment. Before cross-sex hormone administration
to M2F and F2M there was a large overlap in muscle
area between the two but means were significantly
different (Figure 1). This overlap was almost complete
when androgen deprived M2F were compared to non-treated F2M, although means remained significantly
different (Figure 1).
Our data allow the following conclusions: androgen
deprivation in M2F reduces levels of hemoglobin and
IGF-1 to female levels. The reduction in muscle area is
significant but mean muscle area remains significantly
higher than in females but showing an almost complete
overlap. M2F were on average 12 cm taller than F2M.
When androgen deprived M2F were compared to pretreatment F2M in a linear regression model, height was a
strong predictor of muscle area (α = 2.29;
P = 0.001). After correction for the effect of gender, the relation
between height and muscle area remained significant
(α = 1.63; P = 0.036). The reduction in variables three
years after start of cross-sex hormones was not greater
than after one year.
T administration in F2M inducing plasma levels of T
above the references range for eugonadal men increased
muscle area, levels of hemoglobin and IGF-1 to levels of
men. The increases after three years of T administration
were not greater than after one year.
We observed an overlap in muscle area between
non-treated M2F and F2M (Figure 1). Upon androgen
deprivation of M2F the overlap in muscle area with untreated
F2M was almost complete (Figure 1) though the mean
of the muscle area in androgen-deprived M2F remained
above the mean in untreated F2M, but height was a strong
predictor of muscle mass in both groups.
In the case of transsexuals, the further question
arises whether an individual who has undergone normal physical pubertal and post-pubertal development in
one sex, with prolonged exposure to sex appropriate
levels of sex steroids before surgical sex reassignment,
can fairly compete as a member of the other sex. In
terms of actual androgen hormone levels, M2F transsexuals after surgical sex reassignment, have no
competitive advantage over other women, but the effects
of prior androgen exposure on muscle mass and strength
do carry over for a certain time period, making this a
relevant consideration. The fairness of this is
subjective and controversial.
6 Prepubertal administration of cross-sex hormones
The above refers to transsexuals who have undergone sex reassignment postpubertally. Adult
transsexuals often recall that their gender dysphoria started early
in life, well before puberty. Children with gender
identity problems increasingly come to the attention of the
psychomedical care system. From follow-up studies in
cohorts of juvenile transsexuals who have undergone
sex-reassignment treatment, it appears that that they benefit
from somatic treatment [21]. If, in an expert's opinion,
a child's cross-sex gender identity will not change
during long-term follow-up the individual may be spared the
torment of (full) pubescent development of the "wrong"
secondary sex characteristics. Depot forms of LHRH
antagonists/agonists, following the regimen in children
with precocious puberty, can be used when clear signs
of sexual maturation are evident in order to delay
pubertal development until an age that a balanced and
responsible decision can be made to transition to the other sex
[21]. These juvenile transsexuals have never been
exposed to the sex hormones of their natal genetic sex and
their participation in competitive sports is therefore as
much an issue as non-transsexuals who need sex hormone replacement. Such policies are potentially
controversial and are not yet widely adopted.
There will always be an element of arbitrariness in
the drawing of competitive lines. Different individuals
are born with and develop postnatallly different potentials.
The caprices of genetics and postnatal development will
make any form of competition intrinsically unfair at some
level. In the studies of Bhasin and coworkers changes in
muscle size correlated with T dose and concentration
[5, 6]. These correlations were established in groups of
men receiving graded doses of T. There was, however,
considerable heterogeneity in response to T
administration within each group receiving the same amount of T.
These individual differences in response to androgen
administration might reflect differences in activity level, T
metabolism, nutrition, or polymorphisms in androgen
receptor, myostatin, 5α-reductase, or other muscle growth
regulators. The length of CAG tract was, however, only
a weak predictor of change in thigh muscle volume and
lean body mass [6].
7 IOC
The IOC approved the expert panel's recommendation that postpubertal transsexual individuals, both M2F
and F2M, be eligible to compete under the following
criteria [22, 23]:
· Surgical anatomical changes completed, including
external genitalia changes and gonadectomy;
· Legal recognition of their assigned sex has been
conferred by appropriate official authorities;
· Hormonal therapy appropriate for assigned sex has
been administered in a verifiable manner and for a
sufficient length of time to reduce to a minimum
gender-related advantages in sport competitions.
Based on the scientific data available, the expert panel
recommended that eligibility should begin no sooner than
2 years after gonadectomy. Although these criteria have
been widely disseminated in the lay and sports press, not
often appreciated is the fact that the recommendations
included the caveat that every individual would be
assessed on a case-by-case basis, in confidence and that,
in the event that the gender of a competing athlete was
questioned, the medical delegate or equivalent of the
relevant sporting body would have authority to take all
appropriate measures to ascertain the gender of that
competitor. The following are criteria put in place after
genetic-based laboratory screening of female athletes was
discontinued by the IOC in the year 2000 [4]. The IOC
rules, referred to as the Stockholm consensus are spelled
out on the website:
http://www.olympic.org/uk/organisation/commissions/medical/full_story_uk.asp?id=841. Other
websites providing information are:
http://www.uksport.gov.uk/assets/File/Generic_Tem-plate_Documents/Stan
dards_in_Sport/transsexuals.pdf. and
http://www.ausport.gov.au/women/fstrans.asp.
The recommendations are applicable only to elite
competition in events sanctioned by the IOC and, while
not formally binding on other international sports
go-verning bodies, most tend to follow IOC guidelines for
elite sport at international and national level. The further
local application to the entire panoply of sporting events
may be more flexible.
8 Summary and conclusions
Until 2000 the genetic criterion of sex applied in
competitive sports and precluded the participation of
sex reassigned transsexuals as well as other intersexed
individuals. While this criterion has been dropped, it
is still regarded as fair, given the physical
characteristics of the two sexes, that members of the same sex
compete with each other, except for types of competitive sports where the physical differences between
men and women offer no advantage or disadvantage.
Presently, greater weight is given to the essence of
the differences in physical properties between men and
women, which is previous and present exposure to the
anabolic effects of androgens. Upon cessation of the
exposure to androgens, these effects are largely
reversible but is not completely understood whether this
reversibility is truly complete in M2F transsexuals. F2M
transsexuals, similar to hypogonadal men, use T preparation. While their physical properties in the
reassigned state do not offer an obvious advantage over
men, there is a potential of overdosing T. The criterion
adopted by the IOC, that in cases of transsexuals a time
span of two years must have been passed, may be an
acceptable compromise where definitive policy could
become intractably difficult.
References
1 van der Sluis IM, de Ridder MA, Boot AM, Krenning EP, de
Muinck Keizer-Schrama SM. Reference data for bone density
and body composition measured with dual energy x ray
absorptiometry in white children and young adults. Arch Dis
Child 2002; 87: 341_7.
2 Mauras N, Hayes V, Welch S, Rini A, Helgeson K, Dokler M,
et al. Testosterone deficiency in young men: marked alterations in
whole body protein kinetics, strength, and adiposity. J Clin
Endocrinol Metab 1998; 83: 1886_92.
3 Storer TW, Magliano L, Woodhouse L, Lee ML, Dzekov C,
Dzekov J, et al. Testosterone dose-dependently increases
maximal voluntary strength and leg power, but does not affect
fatigability or specific tension. J Clin Endocrinol Metab 2003; 88:
1478_85.
4 Ferguson-Smith MA. Gender verification and the place of XY
females in sports. In: Harries M, Williams C, Stannish WD,
Micheti LJ, editors. Oxford Textbook of Sports Medicine. Oxford:
Oxford Medical Press; 1998. p355_65.
5 Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman
N, et al. Testosterone dose-response relationships in healthy young
men. Am J Physiol Endocrinol Metab 2001; 281: E1172_81.
6 Woodhouse LJ, Reisz-Porszasz S, Javanbakht M, Storer TW, Lee
M, Zerounian H, et al. Development of models to predict
anabolic response to testosterone administration in healthy young
men. Am J Physiol Endocrinol Metab 2003; 284:
E1009_17.
7 Lee PA, Houk CP, Ahmed SF, Hughes IA. Consensus statement
on management of intersex disorders. Pediatrics 2006; 118:
e488_500.
8 Meyer-Bahlburg HF. Gender assignment and reassignment in
intersexuality: controversies, data, and guidelines for research.
Advances in experimental medicine and biology. Adv Exp Med
Biol 2002; 511: 199_223.
9 Hiort O, Thyen U, Holterhus PM. The basis of gender
assignment in disorders of somatosexual differentiation. Horm Res
2005; 64 Suppl 2: 18_22.
10 Bentvelsen FM, Brinkmann AO, van der Schoot P, van der
Linden JE, van der Kwast TH, Boersma WJ, et
al. Developmental pattern and regulation by androgens of androgen receptor
expression in the urogenital tract of the rat. Mol Cell Endocrinol
1995; 113: 245_53.
11 Levy A, Crown A, Reid R. Endocrine intervention for transsexuals.
Clin Endocrinol (Oxf) 2003; 59: 409_18.
12 Moore E, Wisniewski A, Dobs A. Endocrine treatment of
transsexual people: a review of treatment regimens, outcomes, and
adverse effects. J Clin Endocrinol Metab 2003; 88:
3467_73.
13 Gooren L. Hormone treatment of the adult transsexual patient.
Horm Res 2005; 64 Suppl 2: 31_6.
14 Dittrich R, Binder H, Cupisti S, Hoffmann I, Beckmann MW,
Mueller A. Endocrine treatment of male-to-female transsexuals
using gonadotropin-releasing hormone agonist. Exp Clin
Endocrinol Diabetes 2005; 113: 586_92.
15 Mueller A, Kiesewetter F, Binder H, Beckmann MW, Dittrich
R. Long-term administration of testosterone undecanoate
every 3 months for testosterone supplementation in
female-to-male transsexuals. J Clin Endocrinol Metab 2007; 92: 3470_5.
16 Jacobeit JW, Gooren LJ, Schulte HM. Long-acting intramuscular
testosterone undecanoate for treatment of female-to-male
transgender individuals. J Sex Med 2007; 4: 1479_84.
17 Behre HM, Wang C, Handelsman DJ, Nieschlag E.
Pharmaco-logy of testosterone preparations. In: Nieschlag E, Behre HM,
editors. Testosterone: Action, Deficiency, Substitution.
Cambridge: Cambridge University Press; 2004. p405_44.
18 van Kesteren P, Lips P, Deville W, Popp-Snijders C, Asscheman H,
Megens J, et al. The effect of one-year cross-sex hormonal
treatment on bone metabolism and serum insulin-like growth factor-1 in
transsexuals. J Clin Endocrinol Metab 1996; 81: 2227_32.
19 Elbers JM, Asscheman H, Seidell JC, Megens JA, Gooren LJ.
Long-term testosterone administration increases visceral fat in
female to male transsexuals. J Clin Endocrinol Metab 1997; 82:
2044_7.
20 Gooren LJ, Bunck MC. Transsexuals and competitive sports. Eur
J Endocrinol 2004; 151: 425_9.
21 Delemarre-van de Waal HA, Cohen-Kettenis PT. Clinical
management of gender identity disorder in adolescents: a protocol on
psychological and paediatric endocrinology aspects. Eur J
Endocrinol 2006; 155 Suppl 1: S131_7.
22 Ljungqvist A, Genel M. Essay: transsexual athleteswhen is
competition fair? Lancet 2005; 366 Suppl 1: S42_3.
23 Reeser JC. Gender identity and sport: is the playing field level? Br
J Sports Med 2005; 39: 695_9.
|